ASK-120067 clinical trials
How each study uses ASK-120067 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ASK-120067 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 5
Jiangsu Aosaikang Pharmaceutical Co., Ltd. (5) · Hunan Province Tumor Hospital (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · Wen-zhao ZHONG (1) · Shanghai Chest Hospital (1) · Shanghai Pulmonary Hospital, Shanghai, China (1)
Often tested with
Tested in the same studies.
Aflutinib (4) · Rifampin (1) · Itraconazole (1) · Sintilimab (1) · ASKC202 (1) · Sacituzumab tirumotecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test ASK-120067, phase 3 first.
- Oct 2027ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyPhase 3 · Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Dec 2026A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Phase 2 · Shanghai Chest Hospital
Studies
Open first, then newest update. How each study uses ASK-120067 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI TherapyRecruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT07109531Written as ASKC202+ Limertinib
- Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI ProgressionNot yet recruitingPhase 2Hunan Province Tumor HospitalNCT07001995Written as limertinib
- Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain MetastasesNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT07413952Written as Limertinib Plus Radiotherapy
- Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung CancerRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07323056Written as Sacituzumab Tirumotecan and Limertinib
- A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCNot yet recruitingPhase 2Wen-zhao ZHONGNCT07038460Written as Limertinib+sintilimab+chemotherapy
- A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.Not yet recruitingPhase 2Shanghai Chest HospitalNCT06982924Written as Limertinib+bevacizumab
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04143607Written as ASK120067
- Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or ItraconazoleCompletedPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT05631678Written as Rifampicin; ASK120067
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung CancerStatus unknownPhase 1/2Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT03502850Written as ASK120067
- Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy SubjectsCompletedPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT04360915Written as ASK120067
Given beside what is tested · 3 — ASK-120067 is usual care or a partner of the new treatment
- ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLCNot yet recruitingPhase 3Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT07897188Written as Limertinib
- Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT07612137Written as Limertinib
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067RecruitingPhase 1Jiangsu Aosaikang Pharmaceutical Co., Ltd.NCT05306132Written as ASK120067